Oncolytic virus - CZ BioMed Corp

Drug Profile

Oncolytic virus - CZ BioMed Corp

Alternative Names: BRVLYSIN; CERVLYSIN; CORVLYSIN; HERVLYSIN; LURVLYSIN; MERVLYSIN; OVARVLYSIN; PANRVLYSIN; PRORVLYSIN; RVLYSIN

Latest Information Update: 24 Jul 2017

Price : $50

At a glance

  • Originator CZ BioMed Corp
  • Class Oncolytic viruses
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Interferon stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Prostate cancer
  • Preclinical Breast cancer; Cervical cancer; Colorectal cancer; Liver cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer
  • Discontinued Solid tumours

Most Recent Events

  • 24 Jul 2017 CZ Biomed has patent protection for oncolytic virus in USA, Europe, China and Japan (CZ Biomed pipeline, July 2017)
  • 24 Jul 2017 Discontinued - Preclinical for Solid tumours in USA (IV)
  • 24 Jul 2017 Preclinical trials in Breast cancer in USA (IV) (CZ Biomed pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top